A topical product that protects skin from UV exposure
The FDA has approved bemotrizinol (BEMT) for over‑the‑counter sunscreens, marking a modernization in U.S. UV protection. The ingredient absorbs both UVA and UVB rays, is photostable, and will debut as Parsol Shield before broader market adoption after an 18‑month exclusivity period. Industry and dermatology experts say the move could improve protection and user experience, though rollout and formulation timelines remain.
The FDA has approved bemotrizinol, a chemical UV filter used in European and Asian sunscreens for over 20 years. It offers UVA and UVB protection, is photostable, and may lead to more elegant, higher-SPF products in the US. The move comes after decades of FDA inaction on new filters, with products containing bemotrizinol expected to reach US shelves after about 18 months.
Five or more sunburns raise melanoma risk by up to 80%, with age and burn severity shaping outcomes. Experts urge daily sunscreen and preventive care as cases rise across the United States.
Independent and New York Post reports show Dr Sebagh expanding his regenerative skincare line with Exo C Booster, a plant-derived exosome serum, plus injectable autologous exosome treatments in London and Paris clinics. The serum promises immediate radiance and longer-term skin support, while in-clinic treatments aim at cellular regeneration and collagen support. Early SGS data cite increased radiance and firmer skin after 21 days. Pricing remains premium.
A TV presenter’s cervical cancer diagnosis has been re-evaluated after five months of tests; doctors now say the apparent recurrence was a benign neuroma. The diagnosis shift follows extensive re-testing and a high-dose radiotherapy review.